Minuk Gerald Y, Pollock Galia, Uhanova Julia
a Section of Hepatology, Department of Medicine , College of Medicine, University of Manitoba , Winnipeg , Canada.
b Department of Pharmacology and Therapeutics , College of Medicine, University of Manitoba , Winnipeg , Canada.
Int J Circumpolar Health. 2017;76(1):1388104. doi: 10.1080/22423982.2017.1388104.
Despite extensive investigations, some patients have no identifiable cause for their cholestatic liver enzyme abnormalities. The aim of this study was to document the clinical, laboratory, radiologic and histologic features of adult patients with idiopathic cholestasis (AIC). A computerised database of referred patients to a tertiary care hospital outpatient department for assessment of hepatobiliary disorders between 2005 and 2015 was employed to identify and describe features associated with AIC. Of 6,560 patient referrals, sufficient documentation to warrant a diagnosis of AIC was present in 17 (0.26%) cases. Of the 17, a disproportionate number were Canadian Inuit (7/60, 12% Inuit referrals vs. 10/6,500, 0.16% non-Inuit referrals, p<0.0001). The median age of the 17 subjects was 57 years and nine (53%) were female. Clinical and/or laboratory evidence of autoimmune disorders was present in six (35%) cases. Clinical features of hepatic decompensation, radiologic findings in keeping with cirrhosis and histologic confirmation of cirrhosis were present in 47%, 31% and 42% of individuals, respectively. There were no significant improvements in cholestatic liver enzymes and function tests in those treated with ursodiol and/or immunomodulants (n=7) compared to those left untreated (n=10). In conclusion, AIC is a rare condition diagnosed by exclusion. It appears to be more common in the Canadian Inuit population and those with autoimmune disorders. Advanced liver disease is a frequent finding at presentation. Intervention with ursodiol and/or immunomodulants does not appear to be of therapeutic value.
尽管进行了广泛的调查,但仍有一些患者的胆汁淤积性肝酶异常找不到明确病因。本研究的目的是记录成年特发性胆汁淤积症(AIC)患者的临床、实验室、放射学和组织学特征。利用一个计算机化数据库,该数据库记录了2005年至2015年间转诊至一家三级医疗医院门诊部以评估肝胆疾病的患者信息,用于识别和描述与AIC相关的特征。在6560例患者转诊中,有17例(0.26%)有足够的记录以确诊为AIC。在这17例中,加拿大因纽特人所占比例过高(60例中有7例,因纽特人转诊占12%,而非因纽特人转诊为6500例中的10例,占0.16%,p<0.0001)。这17名受试者的中位年龄为57岁,9名(53%)为女性。6例(35%)有自身免疫性疾病的临床和/或实验室证据。分别有47%、31%和42%的个体出现肝失代偿的临床特征、符合肝硬化的放射学表现以及肝硬化的组织学证实。与未接受治疗的患者(n=10)相比,接受熊去氧胆酸和/或免疫调节剂治疗的患者(n=7)的胆汁淤积性肝酶和功能测试无显著改善。总之,AIC是一种通过排除法诊断的罕见疾病。它在加拿大因纽特人群和自身免疫性疾病患者中似乎更为常见。就诊时晚期肝病很常见。使用熊去氧胆酸和/或免疫调节剂进行干预似乎没有治疗价值。